Rab 4A Lentiviral Activation Particles (h): sc-401828-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- Rab 4A Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- Rab 4A Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Rab 4A Lentiviral Activation Plasmid (h) and Rab 4A Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the RAB4A promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: Rab 4A Antibody (4E11): sc-517263
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rab 4A Lentiviral Activation Particles (h) | sc-401828-LAC | 200 µl | $455.00 |
RAB4A encodes Rab 4A, a small GTPase that regulates early endosome dynamics and rapid recycling of internalized membrane proteins back to the plasma membrane. By coordinating vesicle budding, motility, and fusion through interactions with effector proteins, Rab 4A influences receptor trafficking, nutrient uptake, and signal attenuation across pathways such as growth factor receptor recycling and integrin turnover. Altered RAB4A activity has been associated with dysregulated endocytic sorting, changes in cell migration, and remodeling of signaling outputs in cancer and other proliferative or neurodegenerative contexts. As a result, RAB4A is frequently studied to dissect how endosomal transport controls cell-surface receptor availability, downstream kinase signaling, and membrane compartment identity.
Rab 4A Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient RAB4A upregulation across a broader range of human cell types.
Rab 4A Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the RAB4A transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous Rab 4A expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native RAB4A genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.